[go: up one dir, main page]

LT3564378T - Imunogeninė kompozicija - Google Patents

Imunogeninė kompozicija

Info

Publication number
LT3564378T
LT3564378T LTEP19179871.9T LT19179871T LT3564378T LT 3564378 T LT3564378 T LT 3564378T LT 19179871 T LT19179871 T LT 19179871T LT 3564378 T LT3564378 T LT 3564378T
Authority
LT
Lithuania
Prior art keywords
immunogenic composition
immunogenic
composition
Prior art date
Application number
LTEP19179871.9T
Other languages
English (en)
Inventor
Cindy Castado
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46168484&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3564378(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of LT3564378T publication Critical patent/LT3564378T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/55Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP19179871.9T 2011-05-27 2012-05-25 Imunogeninė kompozicija LT3564378T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161490734P 2011-05-27 2011-05-27
US201161490707P 2011-05-27 2011-05-27
US201161490716P 2011-05-27 2011-05-27

Publications (1)

Publication Number Publication Date
LT3564378T true LT3564378T (lt) 2024-01-25

Family

ID=46168484

Family Applications (4)

Application Number Title Priority Date Filing Date
LTEP16193340.3T LT3138916T (lt) 2011-05-27 2012-05-25 Imunogeninė kompozicija
LTEP19179871.9T LT3564378T (lt) 2011-05-27 2012-05-25 Imunogeninė kompozicija
LTEP12724950.6T LT2714910T (lt) 2011-05-27 2012-05-25 Imunogeninė kompozicija
LTEP12726374.7T LT2714911T (lt) 2011-05-27 2012-05-25 Imunogeninė kompozicija

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP16193340.3T LT3138916T (lt) 2011-05-27 2012-05-25 Imunogeninė kompozicija

Family Applications After (2)

Application Number Title Priority Date Filing Date
LTEP12724950.6T LT2714910T (lt) 2011-05-27 2012-05-25 Imunogeninė kompozicija
LTEP12726374.7T LT2714911T (lt) 2011-05-27 2012-05-25 Imunogeninė kompozicija

Country Status (25)

Country Link
US (5) US9290565B2 (lt)
EP (6) EP2714911B1 (lt)
JP (3) JP2014516532A (lt)
KR (1) KR102014502B1 (lt)
CN (3) CN107098977A (lt)
BR (2) BR112013030396A2 (lt)
CA (2) CA2837393A1 (lt)
CY (3) CY1118599T1 (lt)
DK (4) DK2714911T3 (lt)
EA (1) EA030898B1 (lt)
ES (4) ES2743442T3 (lt)
FI (1) FI3564378T3 (lt)
HR (4) HRP20231749T1 (lt)
HU (4) HUE037126T2 (lt)
IL (1) IL229529B2 (lt)
LT (4) LT3138916T (lt)
ME (1) ME02600B (lt)
MX (1) MX346200B (lt)
PL (4) PL3564378T3 (lt)
PT (4) PT2714910T (lt)
RS (1) RS55605B1 (lt)
SG (1) SG195037A1 (lt)
SI (4) SI3564378T1 (lt)
SM (2) SMT201700110T1 (lt)
WO (3) WO2012163810A1 (lt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX350126B (es) 2010-09-03 2017-08-28 Valneva Austria Gmbh Polipéptido aislado de las proteínas de la toxina a y la toxina b de c. difficile y usos del mismo.
HUE047085T2 (hu) 2011-04-22 2020-04-28 Wyeth Llc Clostridium difficile mutáns toxinjához kapcsolódó készítmények és eljárásai
ES2704069T3 (es) 2011-12-08 2019-03-14 Glaxosmithkline Biologicals Sa Vacuna basada en toxinas de Clostridium difficile
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
CN104884081A (zh) * 2012-12-05 2015-09-02 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
CA2910200A1 (en) * 2013-04-22 2014-10-30 Board Of Regents Of The University Of Oklahoma Clostridium difficile vaccine and methods of use
CA2976976C (en) 2015-02-19 2023-02-28 Immune Biosolutions Inc. Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof
JP7426953B2 (ja) * 2018-06-19 2024-02-02 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
EP4531899A1 (en) 2022-06-01 2025-04-09 Valneva Austria GmbH Clostridium difficile vaccine
EP4658302A1 (en) 2023-02-02 2025-12-10 GlaxoSmithKline Biologicals S.A. Immunogenic composition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
DE69535530D1 (de) 1994-10-24 2007-08-16 Ophidian Pharm Inc Impfstoff und Antitoxine zur Behandlung und Vorbeugung von C. Difficile Krankheiten
CN1195297A (zh) * 1995-07-07 1998-10-07 奥拉瓦克斯有限公司 艰难梭菌毒素作为粘膜佐剂
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
EP1169456B1 (en) * 1999-04-09 2012-07-11 Intercell USA, Inc. Recombinant production of Clostridium difficile Toxin A or Toxin B
AU2001251013A1 (en) 2000-03-28 2001-10-08 Diadexus, Inc. Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
CA2733425A1 (en) * 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
US10046040B2 (en) * 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
MX350126B (es) 2010-09-03 2017-08-28 Valneva Austria Gmbh Polipéptido aislado de las proteínas de la toxina a y la toxina b de c. difficile y usos del mismo.
GB201016742D0 (en) * 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens

Also Published As

Publication number Publication date
LT3138916T (lt) 2019-08-26
US20160159867A1 (en) 2016-06-09
EP2714910A1 (en) 2014-04-09
PT2714910T (pt) 2018-03-09
CN107098977A (zh) 2017-08-29
JP2014522238A (ja) 2014-09-04
EP3564378B1 (en) 2023-11-01
MX2013013924A (es) 2013-12-16
FI3564378T3 (fi) 2024-01-18
SI2714911T1 (sl) 2017-03-31
SI3138916T1 (sl) 2019-08-30
EA201391548A1 (ru) 2014-06-30
ES2968455T3 (es) 2024-05-09
HUE030823T2 (en) 2017-06-28
EP3327126A1 (en) 2018-05-30
ES2615737T3 (es) 2017-06-08
LT2714910T (lt) 2018-03-12
US9290565B2 (en) 2016-03-22
BR112013030396A2 (pt) 2016-12-13
PL2714911T3 (pl) 2017-05-31
DK3564378T3 (da) 2024-01-08
HRP20180339T1 (hr) 2018-03-23
BR112013030395A2 (pt) 2016-12-13
CA2837393A1 (en) 2012-12-06
CN103717742B (zh) 2018-05-22
HUE037126T2 (hu) 2018-08-28
CY1119916T1 (el) 2018-06-27
US20140093529A1 (en) 2014-04-03
JP2017012160A (ja) 2017-01-19
CA2837395C (en) 2021-05-18
HRP20191291T1 (hr) 2019-10-18
DK3564378T5 (da) 2024-09-02
EP3138916A1 (en) 2017-03-08
US20170247421A1 (en) 2017-08-31
ES2660468T3 (es) 2018-03-22
ES2743442T3 (es) 2020-02-19
EP3138916B1 (en) 2019-06-19
HRP20231749T1 (hr) 2024-03-15
SG195037A1 (en) 2013-12-30
WO2012163817A3 (en) 2013-03-21
PL3564378T3 (pl) 2024-03-11
MX346200B (es) 2017-03-10
EA030898B1 (ru) 2018-10-31
DK2714911T3 (en) 2017-02-27
CY1118599T1 (el) 2017-07-12
IL229529B2 (en) 2023-05-01
CN103732750A (zh) 2014-04-16
HUE064492T2 (hu) 2024-03-28
PT3564378T (pt) 2024-01-26
EP2714911A2 (en) 2014-04-09
DK3138916T3 (da) 2019-08-26
US9409974B2 (en) 2016-08-09
JP5952390B2 (ja) 2016-07-13
EP3564378A1 (en) 2019-11-06
JP2014516532A (ja) 2014-07-17
HUE044772T2 (hu) 2019-11-28
EP2714911B1 (en) 2016-11-30
CA2837395A1 (en) 2012-12-06
US10377816B2 (en) 2019-08-13
US10093722B2 (en) 2018-10-09
ME02600B (me) 2017-06-20
PL3138916T3 (pl) 2019-11-29
SI3564378T1 (sl) 2024-02-29
WO2012163811A1 (en) 2012-12-06
IL229529B1 (en) 2023-01-01
EP2714910B1 (en) 2018-01-10
CY1121936T1 (el) 2020-10-14
SMT201700110T1 (it) 2017-03-08
EP4296361A2 (en) 2023-12-27
KR102014502B1 (ko) 2019-08-26
HRP20170094T1 (hr) 2017-03-24
IL229529A0 (en) 2014-01-30
DK2714910T3 (en) 2018-02-05
US20170362309A1 (en) 2017-12-21
US9644024B2 (en) 2017-05-09
PL2714910T3 (pl) 2018-06-29
US20140178424A1 (en) 2014-06-26
WO2012163817A2 (en) 2012-12-06
BR112013030395B1 (pt) 2022-11-01
LT2714911T (lt) 2017-02-10
EP4296361A3 (en) 2024-02-28
KR20140019848A (ko) 2014-02-17
PT2714911T (pt) 2017-02-06
SI2714910T1 (en) 2018-04-30
CN103717742A (zh) 2014-04-09
RS55605B1 (sr) 2017-06-30
WO2012163810A1 (en) 2012-12-06
PT3138916T (pt) 2019-09-17
SMT201700110B (it) 2017-03-08

Similar Documents

Publication Publication Date Title
GB201003924D0 (en) Immunogenic composition
ZA201503927B (en) Immunogenic composition
SG11201404447WA (en) Immunogenic composition
SI3138916T1 (sl) Imunogeni sestavek
ZA201308399B (en) Improved composition
IL238079A0 (en) Immunogenic preparation
SG10201702685WA (en) Immunogenic composition
GB201223342D0 (en) Immunogenic composition
GB201218660D0 (en) Immunogenic composition
GB201117037D0 (en) Composition
GB201103964D0 (en) Composition
EP2711011A4 (en) COMPOSITION CONTAINING PANAXADIOL
GB201216884D0 (en) Composition
GB201204968D0 (en) Immunogenic composition
GB201204851D0 (en) Immunogenic composition
GB201003918D0 (en) Immunogenic composition
GB201106497D0 (en) Composition
GB201118516D0 (en) Composition
GB201110241D0 (en) Composition